Four drugmakers found to have breached ABPI code
pharmaphorum
JULY 7, 2024
Novartis, Pfizer, Otsuka and Novo Nordisk have been called out for breaching the ABPI code of practice
Sun.Jul 07, 2024
115 
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
JAMA Internal Medicine
JULY 7, 2024
This cohort study compares treatment-associated weight loss and rates of gastrointestinal adverse events among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes in a clinical setting.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Developers Tap the Immune System to Supercharge ADCs
BioSpace
JULY 7, 2024
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.
Less than Meets the Eye: LDT Small Entity Compliance Guide Adds Little Insight
FDA Law Blog
JULY 7, 2024
By Gail H. Javitt — In its final rule on laboratory developed tests (LDTs) (see our prior blog here ), FDA acknowledged that “some laboratories may lack familiarity, experience, or existing infrastructure for complying with FDA requirements” and made multiple references to a “small entity compliance guidance” that the agency intended to publish to “provide additional guidance to small businesses.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Beyond GLP-1s: The Next Obesity Treatments
BioSpace
JULY 7, 2024
Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
Introduction Atopic Dermatitis (AD) is one of the most prevalent skin conditions worldwide. In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. This blog post explores the key measurement tools used in AD trials, specifically the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA),
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Which pharmaceutical drugs have the most drug patents in France?
Drug Patent Watch
JULY 7, 2024
This chart shows the drugs with the most patents in France. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
Introduction Atopic Dermatitis (AD) is one of the most prevalent skin conditions worldwide. In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. This blog post explores the key measurement tools used in AD trials, specifically the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA),
New tentative approval for Alembic drug dabigatran etexilate mesylate
Drug Patent Watch
JULY 7, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
Introduction Atopic Dermatitis (AD) is one of the most prevalent skin conditions worldwide. In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. This blog post explores the key measurement tools used in AD trials, specifically the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA),
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
Introduction Atopic Dermatitis (AD) is one of the most prevalent skin conditions worldwide. In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. This blog post explores the key measurement tools used in AD trials, specifically the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA),
Let's personalize your content